Guilherme Renke

ORCID: 0000-0002-7940-3667 · 4 papers in corpus
article 2025
Comparison between the effects of implantable gestrinone and oral dienogest in the treatment of endometriosis: randomized controlled clinical trial
·doi:10.1016/j.maturitas.2025.108519
review 2025
New Perspectives on the Use of Resveratrol in the Treatment of Metabolic and Estrogen-Dependent Conditions Through Hormonal Modulation and Anti-Inflammatory Effects
Current issues in molecular biology ·doi:10.3390/cimb47090692

Estrogen-dependent conditions, such as endometriosis, adenomyosis, lipedema, polycystic ovary syndrome, and breast cancer, are intimately involved with hormonal changes related to estrogen and their receptors. These conditions can be expres…

other 2024
Effects, Doses, and Applicability of Gestrinone in Estrogen-Dependent Conditions and Post-Menopausal Women
Pharmaceuticals (Basel, Switzerland) ·doi:10.3390/ph17091248

Gestrinone (R-2323), or ethylnorgestrienone, is a synthetic steroid of the 19-nortestosterone group more commonly used as an oral, intravaginal, or subcutaneous implant for the treatment of endometriosis, contraception, and estrogen-depende…

review 2023
Clinical Approaches to Nestorone Subdermal Implant Therapy in Women's Health
Biomedicines ·doi:10.3390/biomedicines11092586

Segesterone acetate (SA) or Nestorone, a fourth-generation progestogen, is a synthetic compound with high progestational activity and no androgenic, glucocorticoid, or anabolic effects. However, due to its oral inactivity, SA must be used b…